Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-11-22

Clinical Trial Update: Fesoterodine "add-on" Male Overactive Bladder Study [Phase 3]

View source ↗

Summary

Phase 3 trial update for fesoterodine as add-on therapy in men with overactive bladder. The study is completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fesoterodine (fesoterodine)

Snippet

Sponsor: Pfizer | Conditions: Overactive Bladder Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2010-11-22